Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 2/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.31 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15186915 | 0.83 | PARP1 (0.33) | LPLLIPGPARP1 | |
| SCHEMBL12890291 | 0.80 | PARP1 (0.31) | PARP1 | |
| SCHEMBL15186949 | 0.79 | LPL (0.33) | LPLLIPGPARP1 | |
| SCHEMBL18552592 | 0.79 | PRKCQ (0.35) | — | |
| SCHEMBL18552652 | 0.79 | MTNR1A (0.39) | PARP1 | |
| SCHEMBL1565470 | 0.78 | LPL (0.36) | LPLLIPGPARP1 | |
| SCHEMBL29763539 | 0.77 | LPL (0.33) | LPLLIPG | |
| SCHEMBL28974108 | 0.76 | KEAP1 (0.39) | LPLLIPG | |
| SCHEMBL21542750 | 0.76 | IDO1 (0.37) | LPLLIPGTRPA1 | |
| SCHEMBL31481795 | 0.75 | TNF (0.45) | LPLLIPGGPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12595255-B2 | Heteroaryl-substituted imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2026-04-07 | — | — | US | disclosed |
| CN-118888845-A | Electrolyte and lithium ion battery | 惠州亿纬锂能股份有限公司 | 2024-11-01 | — | — | CN | disclosed |
| US-12110293-B2 | Substituted triazolo quinoxaline derivatives | Grünenthal GmbH (DE) | 2024-10-08 | — | — | US | disclosed |
| US-20240327416-A1 | Further Substituted Triazolo Quinoxaline Derivatives | GRUENENTHAL GMBH (DE) | 2024-10-03 | — | — | US | disclosed |
| US-11981677-B2 | Further substituted triazolo quinoxaline derivatives | Grünenthal GmbH (DE) | 2024-05-14 | — | — | US | disclosed |
| EP-3823970-B1 | FURTHER SUBSTITUTED TRIAZOLO QUINOXALINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2024-01-03 | — | — | EP | disclosed |
| US-20230373978-A1 | HETEROARYL-SUBSTITUTED IMIDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-11-23 | — | — | US | disclosed |
| CN-116829546-A | Novel heteroaryl substituted imidazole derivatives | 豪夫迈·罗氏有限公司 | 2023-09-29 | — | — | CN | disclosed |
| EP-3823971-B1 | SUBSTITUTED TRIAZOLO QUINOXALINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2022-07-27 | — | — | EP | disclosed |
| CN-108137613-B | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors | 卡鲁斯治疗有限公司 | 2021-10-01 | — | — | CN | disclosed |
| WO-2009053715-A1 | THIENOPYRIMIDIENE DERIVATIVES AS PI3K INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-30 | — | — | WO | disclosed |
| WO-2008152390-A1 | THIAZOLIOPYRIMIDINES AND THEIR USE AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3 KINASE | F.HOFFMANN-LA ROCHE AG (CH) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008152387-A1 | QUINAZOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008152387-A1 | QUINAZOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008152394-A1 | PHARMACEUTICAL COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008125833-A1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008125839-A2 | PYRIMIDINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3-KINASE | PIRAMED LIMITED (GB) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008125839-A2 | PYRIMIDINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3-KINASE | PIRAMED LIMITED (GB) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008125835-A1 | 2-MORPHOLIN-4-YL-PYRIMIDINES AS PI3K INHIBITORS | PIRAMED LIMITED (GB) | 2008-10-23 | — | — | WO | disclosed |
| WO-2007122410-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327416-A1 | Further Substituted Triazolo Quinoxaline Derivatives | NR3C1, GRK5, NR3C2 | LPL 4179/4885LIPG 2444/4885PARP1 3234/4885 |
| US-11981677-B2 | Further substituted triazolo quinoxaline derivatives | NR3C1, GRK5, NR3C2 | LPL 4179/4885LIPG 2444/4885PARP1 3234/4885 |
| US-20230373978-A1 | HETEROARYL-SUBSTITUTED IMIDAZOLE DERIVATIVES | F3, ABL1, CFTR | LPL 3950/4885LIPG 4311/4885PARP1 2923/4885 |
| US-12595255-B2 | Heteroaryl-substituted imidazole derivatives | CLIC1, CYP2B6, CYP2D6 | LPL 2999/4885LIPG 2675/4885PARP1 2856/4885 |
| US-12110293-B2 | Substituted triazolo quinoxaline derivatives | NR3C1, NR3C2, GRK5 | LPL 4415/4885LIPG 2751/4885PARP1 3012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.